| [1] |
LDe La Rosette J, Assimos D, Desai M, et al. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5 803 patients[J]. J Endourol, 2011, 25(1): 11-17.
|
| [2] |
Liu C, Zhang X, Liu Y, et al. Prevention and treatment of septic shock following mini-percutaneous nephrolithotomy: a single-center retrospective study of 834 cases[J]. World J Urol, 2013, 31(6): 1593-1597.
|
| [3] |
Roushani A, Falahatkar S, Sharifi S H, et al. Intra-operative stone culture as an independent predictor of systemic inflammatory response syndrome after percutaneous nephrolithotomy[J]. Urolithiasis, 2014, 42(5): 455-459.
|
| [4] |
Sharifi Aghdas F, Akhavizadegan H, Aryanpoor A, et al. Fever after percutaneous nephrolithotomy: contributing factors[J]. Surg Infect (Larchmt), 2006, 7(4): 367-371.
|
| [5] |
Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials[J]. Arch Intern Med, 2012, 172(13): 988-996.
|
| [6] |
Minardi D, D'anzeo G, Cantoro D, et al. Urinary tract infections in women: etiology and treatment options[J]. Int J Gen Med, 2011, 4: 333-343.
|
| [7] |
Zhu ZJ, Xu QQ, Huang XB, et al. [Risk factor analysis of systemic inflammatory response syndrome in type 2 diabetics after percutaneous nephrolithotomy][J]. Beijing Da Xue Xue Bao Yi Xue Ban, 2016, 48(4): 643-649.
|
| [8] |
Gutierrez J, Smith A, Geavlete P, et al. Urinary tract infections and post-operative fever in percutaneous nephrolithotomy[J]. World J Urol, 2013, 31(5): 1135-1140.
|
| [9] |
Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start[J]. Nat Rev Drug Discov, 2014, 13(6): 465-476.
|
| [10] |
Patel N, Shi W, Liss M, et al. Multidrug resistant bacteriuria before percutaneous nephrolithotomy predicts for postoperative infectious complications[J]. J Endourol, 2015, 29(5): 531-536.
|
| [11] |
Eswara J R, Lee H, Dretler S P, et al. The effect of delayed percutaneous nephrolithotomy on the risk of bacteremia and sepsis in patients with neuromuscular disorders[J]. World J Urol, 2013, 31(6): 1611-1165.
|
| [12] |
Nevo A, Mano R, Baniel J, et al. Ureteric stent dwelling time: a risk factor for post-ureteroscopy sepsis[J]. BJU Int, 2017, 120(1): 117-122.
|
| [13] |
Sohn DW, Kim SW, Hong CG, et al. Risk factors of infectious complication after ureteroscopic procedures of the upper urinary tract[J]. J Infect Chemother, 2013, 19(6): 1102-1108.
|
| [14] |
Nevo A, Mano R, Schreter E, et al. Clinical Implications of Stent Culture in Patients with Indwelling Ureteral Stents Prior to Ureteroscopy[J]. J Urol, 2017, 198(1): 116-121.
|
| [15] |
Wang Y, Jiang F, Wang Y, et al. Post-percutaneous nephrolithotomy septic shock and severe hemorrhage: a study of risk factors[J]. Urol Int, 2012, 88(3): 307-310.
|
| [16] |
Yang T, Liu S, Hu J, et al. The evaluation of risk factors for postoperative infectious complications after percutaneous nephrolithotomy[J]. Biomed Res Int, 2017, 2017: 4832051.
|
| [17] |
Mariappan P, Smith G, Moussa S A, et al. One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study[J]. BJU Int, 2006, 98(5): 1075-1079.
|
| [18] |
Mariappan P, Smith G, Bariol SV, et al. Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study[J]. J Urol, 2005, 173(5): 1610-1614.
|
| [19] |
Etemadian M, Haghighi R, Madineay A, et al. Delayed versus same-day percutaneous nephrolithotomy in patients with aspirated cloudy urine[J]. Urol J, 2008, 5(1): 28-33.
|
| [20] |
Michel MS, Trojan L, Rassweiler JJ. Complications in percutaneous nephrolithotomy[J]. Eur Urol, 2007, 51(4): 899-906.
|
| [21] |
Rivera M, Viers B, Cockerill P, et al. Pre- and postoperative predictors of infection-related complications in patients undergoing percutaneous nephrolithotomy[J]. J Endourol, 2016, 30(9): 982-986.
|
| [22] |
Mcaleer IM, Kaplan GW, Bradley JS, et al. Endotoxin content in renal calculi[J]. J Urol, 2003, 169(5): 1813-1814.
|
| [23] |
Dogan HS, Guliyev F, Cetinkaya YS, et al. Importance of microbiological evaluation in management of infectious complications following percutaneous nephrolithotomy[J]. Int Urol Nephrol, 2007, 39(3): 737-742.
|
| [24] |
Zhong W, Zeng G, Wu K, et al. Does a smaller tract in percutaneous nephrolithotomy contribute to high renal pelvic pressure and postoperative fever?[J]. J Endourol, 2008, 22(9): 2147-2151.
|
| [25] |
Kyriazis I, Panagopoulos V, Kallidonis P, et al. Complications in percutaneous nephrolithotomy[J]. World J Urol, 2015, 33(8): 1069-1077.
|
| [26] |
Schilling D, Gakis G, Walcher U, et al. The learning curve in minimally invasive percutaneous nephrolitholapaxy: a 1-year retrospective evaluation of a novice and an expert[J]. World J Urol, 2011, 29(6): 749-753.
|
| [27] |
Tanriverdi O, Boylu U, Kendirci M, et al. The learning curve in the training of percutaneous nephrolithotomy[J]. Eur Urol, 2007, 52(1): 206-211.
|
| [28] |
Zhong Q, Zheng C, Mo J, et al. Total tubeless versus standard percutaneous nephrolithotomy: a meta-analysis[J]. J Endourol, 2013, 27(4): 420-426.
|
| [29] |
Amer T, Ahmed K, Bultitude M, et al. Standard versus tubeless percutaneous nephrolithotomy: a systematic review[J]. Urol Int, 2012, 88(4): 373-382.
|
| [30] |
Draga RO, Kok ET, Sorel MR, et al. Percutaneous nephrolithotomy: factors associated with fever after the first postoperative day and systemic inflammatory response syndrome[J]. J Endourol, 2009, 23(6): 921-927.
|
| [31] |
Maki KC, Kaspar KL, Khoo C, et al. Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection[J]. Am J Clin Nutr, 2016, 103(6): 1434-1442.
|
| [32] |
Beerepoot M, Geerlings S. Non-Antibiotic Prophylaxis for Urinary Tract Infections[J]. Pathogens, 2016, 5(2):36.
|
| [33] |
Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review[J]. Obstet Gynecol, 2014, 124(6): 1147-1156.
|
| [34] |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377.
|
| [35] |
Ordon M, Kodama R, Honey RJ. Re: Best practice policy statement on urologic surgery antimicrobial prophylaxis. J. S. Wolf, Jr., C. J. Bennett, R. R. Dmochowski, B. K. Hollenbeck, M. S. Pearle and A. J. Schaeffer. J Urol, 2008, 179: 1379-1390[J]. J Urol, 2009, 182(2): 799-801.
|
| [36] |
Bag S, Kumar S, Taneja N, et al. One week of nitrofurantoin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study[J]. Urology, 2011, 77(1): 45-49.
|
| [37] |
Bossink AW, Groeneveld AB, Hack CE, et al. The clinical host response to microbial infection in medical patients with fever[J]. Chest, 1999, 116(2): 380-390.
|
| [38] |
Erb L, Hyman NH, Osler T. Abnormal vital signs are common after bowel resection and do not predict anastomotic leak[J]. J Am Coll Surg, 2014, 218(6): 1195-1199.
|
| [39] |
Russo P R, Landon M, Burkard JF, et al. Fever evaluation cost and time to treatment in the general surgery patient can be reduced by using a fever practice guideline[J]. Mil Med, 2014, 179(10): 1166-70.
|
| [40] |
Bozkurt IH, Aydogdu O, Yonguc T, et al. Predictive Value of Leukocytosis for Infectious Complications After Percutaneous Nephrolithotomy[J]. Urology, 2015, 86(1): 25-29.
|
| [41] |
Jones SL, Ashton CM, Kiehne L, et al. Reductions in sepsis mortality and costs after design and implementation of a nurse-based early recognition and response program[J]. Jt Comm J Qual Patient Saf, 2015, 41(11): 483-491.
|
| [42] |
Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis[J]. Crit Care Med, 2010, 38(2): 367-374.
|
| [43] |
Levy MM, Rhodes A, Phillips GS, et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study[J]. Crit Care Med, 2015, 43(1): 3-12.
|
| [44] |
Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis[J]. PLoS One, 2015, 10(8): e0129305.
|
| [45] |
Keh D, Trips E, Marx G, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the hypress randomized clinical trial[J]. JAMA, 2016, 316(17): 1775-1785.
|
| [46] |
Zadroga R, Williams DN, Gottschall R, et al. Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy[J]. Clin Infect Dis, 2013, 56(6): 790-797.
|
| [47] |
Cardoso T, Carneiro A H, Ribeiro O, et al. Reducing mortality in severe sepsis with the implementation of a core 6-hour bundle: results from the Portuguese community-acquired sepsis study (SACiUCI study)[J]. Crit Care, 2010, 14(3): R83.
|
| [48] |
Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program[J]. Crit Care Med, 2014, 42(8): 1749-1755.
|